Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.

Peters JU, Hoffmann T, Schnider P, Stadler H, Koblet A, Alker A, Poli SM, Ballard TM, Spooren W, Steward L, Sleight AJ.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3405-8. doi: 10.1016/j.bmcl.2010.04.008. Epub 2010 Apr 9.

PMID:
20430616
2.

Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht(6) receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task.

King MV, Spicer CH, Sleight AJ, Marsden CA, Fone KC.

Psychopharmacology (Berl). 2009 Jan;202(1-3):111-23. doi: 10.1007/s00213-008-1334-1. Epub 2008 Oct 7.

PMID:
18839151
3.

Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.

Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen C, Zenner MT, Kolb Y, Marcuz A, Huwyler J, Nakagawa T, Porter RH, Thomas AW, Wettstein JG, Sleight AJ, Spooren W, Prinssen EP.

Br J Pharmacol. 2008 Jun;154(4):797-811. doi: 10.1038/bjp.2008.135. Epub 2008 Apr 21.

4.

Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.

Hoffmann T, Bös M, Stadler H, Schnider P, Hunkeler W, Godel T, Galley G, Ballard TM, Higgins GA, Poli SM, Sleight AJ.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1362-5. Epub 2005 Dec 5.

PMID:
16332435
5.

5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism.

King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC.

Neuropharmacology. 2004 Aug;47(2):195-204.

PMID:
15223298
6.

Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790.

Woolley ML, Marsden CA, Sleight AJ, Fone KC.

Psychopharmacology (Berl). 2003 Dec;170(4):358-67. Epub 2003 Sep 10.

PMID:
13680084
7.

Parallel solution- and solid-phase synthesis of spiropyrrolo-pyrroles as novel neurokinin receptor ligands.

Bleicher KH, Wüthrich Y, Adam G, Hoffmann T, Sleight AJ.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3073-6.

PMID:
12372504
8.

Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands.

Bleicher KH, Wüthrich Y, De Boni M, Kolczewski S, Hoffmann T, Sleight AJ.

Bioorg Med Chem Lett. 2002 Sep 16;12(18):2519-22.

PMID:
12182851
9.

A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze.

Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC.

Neuropharmacology. 2001 Aug;41(2):210-9.

PMID:
11489457
10.

5-HT(6) receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides.

Bös M, Sleight AJ, Godel T, Martin JR, Riemer C, Stadler H.

Eur J Med Chem. 2001 Feb;36(2):165-78.

PMID:
11311747
11.

Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.

Bentley JC, Bourson A, Boess FG, Fone KC, Marsden CA, Petit N, Sleight AJ.

Br J Pharmacol. 1999 Apr;126(7):1537-42.

12.

Residues in transmembrane regions III and VI contribute to the 5-ht6 receptor ligand binding site.

Boess FG, Monsma FJ Jr, Bourson A, Zwingelstein C, Sleight AJ.

Ann N Y Acad Sci. 1998 Dec 15;861:242-3. No abstract available.

PMID:
9928266
13.

The putative 5-ht6 receptor: localization and function.

Sleight AJ, Boess FG, Bös M, Bourson A.

Ann N Y Acad Sci. 1998 Dec 15;861:91-6. Review.

PMID:
9928244
14.

Involvement of 5-HT6 receptors in nigro-striatal function in rodents.

Bourson A, Boess FG, Bös M, Sleight AJ.

Br J Pharmacol. 1998 Dec;125(7):1562-6.

16.

The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.

Boess FG, Riemer C, Bös M, Bentley J, Bourson A, Sleight AJ.

Mol Pharmacol. 1998 Sep;54(3):577-83.

PMID:
9730917
17.

5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.

Martin JR, Bös M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Köhler C, Delft AM.

J Pharmacol Exp Ther. 1998 Aug;286(2):913-24.

PMID:
9694950
18.

Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors.

Sleight AJ, Boess FG, Bös M, Levet-Trafit B, Riemer C, Bourson A.

Br J Pharmacol. 1998 Jun;124(3):556-62.

19.

O-methylasparvenone, a nitrogen-free serotonin antagonist.

Bös M, Canesso R, Inoue-Ohga N, Nakano A, Takehana Y, Sleight AJ.

Bioorg Med Chem. 1997 Dec;5(12):2165-71.

PMID:
9459014
20.

Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice.

Bourson A, Kapps V, Zwingelstein C, Rudler A, Boess FG, Sleight AJ.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):820-6.

PMID:
9453469
21.

Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.

Boess FG, Monsma FJ Jr, Meyer V, Zwingelstein C, Sleight AJ.

Mol Pharmacol. 1997 Sep;52(3):515-23.

PMID:
9284367
23.

Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.

Boess FG, Monsma FJ Jr, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ.

Neuropharmacology. 1997 Apr-May;36(4-5):713-20.

PMID:
9225298
24.

Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.

Sleight AJ, Stam NJ, Mutel V, Vanderheyden PM.

Biochem Pharmacol. 1996 Jan 12;51(1):71-6.

PMID:
8534270
25.

Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine.

Bourson A, Wanner D, Wyler R, Petit N, Zwingelstein C, Rudler A, Sleight AJ.

Pharmacol Biochem Behav. 1996 Jan;53(1):107-14.

PMID:
8848438
26.

Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides.

Sleight AJ, Monsma FJ Jr, Borroni E, Austin RH, Bourson A.

Behav Brain Res. 1996;73(1-2):245-8.

PMID:
8788511
27.

Prolonged sedation due to accumulation of conjugated metabolites of midazolam.

Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE.

Lancet. 1995 Jul 15;346(8968):145-7.

PMID:
7603229
28.

Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.

Bourson A, Borroni E, Austin RH, Monsma FJ Jr, Sleight AJ.

J Pharmacol Exp Ther. 1995 Jul;274(1):173-80.

PMID:
7616396
29.
30.

Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment.

Sleight AJ, Carolo C, Petit N, Zwingelstein C, Bourson A.

Mol Pharmacol. 1995 Jan;47(1):99-103.

PMID:
7838138
31.
32.
33.

Characterization of a novel and potent 5-hydroxytryptamine1A receptor antagonist.

Liau LM, Sleight AJ, Pitha J, Peroutka SJ.

Pharmacol Biochem Behav. 1991 Mar;38(3):555-9.

PMID:
1648748
34.

Structural determinants of 5-HT1A versus 5-HT1D receptor binding site selectivity.

Harrington MA, Sleight AJ, Pitha J, Peroutka SJ.

Eur J Pharmacol. 1991 Feb 26;194(1):83-90.

PMID:
2060596
35.

Identification of 5-hydroxytryptamine1A receptor agents using a composite pharmacophore analysis and chemical database screening.

Sleight AJ, Peroutka SJ.

Naunyn Schmiedebergs Arch Pharmacol. 1991 Feb;343(2):109-16.

PMID:
2067585
36.

In vivo effects of sumatriptan (GR 43175) on extracellular levels of 5-HT in the guinea pig.

Sleight AJ, Cervenka A, Peroutka SJ.

Neuropharmacology. 1990 Jun;29(6):511-3.

PMID:
2166920
37.

Serotonin receptor "families" in the central nervous system: an overview.

Peroutka SJ, Schmidt AW, Sleight AJ, Harrington MA.

Ann N Y Acad Sci. 1990;600:104-12; discussion 113. Review. No abstract available.

PMID:
2252304
38.
39.

The effects of chronic treatment with amitriptyline and MDL 72394 on the control of 5-HT release in vivo.

Sleight AJ, Smith RJ, Marsden CA, Palfreyman MG.

Neuropharmacology. 1989 May;28(5):477-80.

PMID:
2725855
40.

Functional identification of 5HT receptor subtypes.

Marsden CA, Sleight AJ, Fone KC, Jonson JV, Crespi F, Martin KF, Garrett JC, Bennett GW.

Comp Biochem Physiol A Comp Physiol. 1989;93(1):107-14. Review. No abstract available.

PMID:
2568213
41.

The clinical utility of pharmacological agents that act at serotonin receptors.

Peroutka SJ, Sleight AJ, McCarthy BG, Pierce PA, Schmidt AW, Hekmatpanah CR.

J Neuropsychiatry Clin Neurosci. 1989 Summer;1(3):253-62. Review.

PMID:
2562495
42.

Chronic MAO A and MAO B inhibition decreases the 5-HT1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase.

Sleight AJ, Marsden CA, Palfreyman MG, Mir AK, Lovenberg W.

Eur J Pharmacol. 1988 Sep 23;154(3):255-61.

PMID:
3234480
43.
44.

Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase.

Palfreyman MG, McDonald IA, Fozard JR, Mely Y, Sleight AJ, Zreika M, Wagner J, Bey P, Lewis PJ.

J Neurochem. 1985 Dec;45(6):1850-60.

PMID:
3840523

Supplemental Content

Loading ...
Support Center